NCT05633602 2026-04-17
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
SWOG Cancer Research Network
City of Hope Medical Center
SWOG Cancer Research Network
Pfizer
PrECOG, LLC.
Institut Paoli-Calmettes